Comparison of Whole Body DWI to FDG PET
Part of paid clinical trials in San Francisco, California.
- Sponsor
- University of California, San Francisco
- Study ID
- NCT06630845
- Status
- Recruiting
Conditions
- Metastatic Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Fluorodeoxyglucose F18 — DRUGGiven IV as part of routine imaging
- Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI) — PROCEDUREImaging procedure
- Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI) — PROCEDUREImaging procedure done concurrently with PET/MRI
- General Electric (GE) SIGNA PET/MR — DEVICEImaging device
Study Details
This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.
Key Dates
- Start date
- Feb 6, 2025
- Status verified
- Mar 2026
- Primary completion
- Oct 31, 2027
- Completion
- Oct 31, 2029
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: Whole Body DWI plus FDG PET/MRIParticipants will receive 5 to 10 Megabecquerel (MBq) +/- 10% of 18F-fluorodeoxyglucose as an intravenous injection and undergo a FDG PET/MRI scan that will extend from the vertex to the mid-thighs. Imaging will be performed from vertex to mid-thighs using standard protocol. Participants may also obtain an optional second FDG PET/MRI with DWI within 6 months.
Primary Outcome Measure
Proportion of lesions characterized as positive [ Time Frame: Up to 6 months ]
Central Contacts
- Brad Kline877-827-3222
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94143 | Brad Kline 877-827-3222 Thomas Hope, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in San Francisco, CA
By research site
Related Studies
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- Imaging of Solid Tumors Using FAP-2286PHASE1 · Recruiting · Thomas Hope · San Francisco, California
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · Artios Pharma Ltd · Birmingham, Alabama
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsPHASE1 · Recruiting · I-Mab Biopharma US Limited · Orange, California